Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma

  • STATUS
    Recruiting
  • End date
    Dec 25, 2021
  • participants needed
    30
  • sponsor
    Massachusetts General Hospital
Updated on 25 January 2021
schwannoma
measurable disease
tumor growth

Summary

In this research study we are looking at another type of radiation called proton radiation which is known to spare surrounding normal tissues from radiation. The proton radiation will be delivered using fractionated stereotactic radiotherapy (FSRT) to improve localization of the small tumor target. Proton radiation delivers minimal radiation beyond the area of the tumor. This may reduce side effects that patients would normally experience with conventional radiation therapy. In this research study, we are looking to determine the effects of fractionated proton radiotherapy on long-term hearing preservation and controlling tumor growth.

Description

  • Proton radiation will be delivered daily for approximately 5.5 weeks. Participants will be assessed weekly for any side effects they may be experiencing.
    • Participants will have a follow-up visit 6 months after their last proton radiation treatment and then every year from the time of treatment completion for 5 years. The following tests and procedures will be performed at these visits: medical history, physical exam, MRI scan, comprehensive hearing tests and a questionnaire.

Details
Condition Acoustic Neuroma, vestibular schwannoma
Treatment Fractionated proton radiation
Clinical Study IdentifierNCT01199978
SponsorMassachusetts General Hospital
Last Modified on25 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

MRI confirmed unilateral vestibular schwannoma within 8 weeks prior to study entry
Measurable disease, defined as a lesion that can be accurately measured in at least one dimension
No prior radiotherapy with dose delivered to structures in proximity to the internal acoustic canal is allowable
Participants must have baseline "useful hearing" defined at the discretion of the treating physician in the irradiated ear
years of age or older
Life expectancy of greater than 60 months
Karnofsky performance status 60 or greater
Women of child-bearing potential and men must agree to use adequate contraception during the interval of irradiation
Able to tolerate the supine position as required for the radiation treatment unit and able to tolerate rotation needed for treatment delivery
Willing and able to comply with comprehensive audiologic testing, at baseline prior to radiation therapy, at 6 months from treatment completion, and at annual timepoints for 5 years after completion

Exclusion Criteria

Participants who have had prior radiotherapy, with dose delivered to structures in proximity to the internal acoustic canal
Participants with tumors (or residual tumor after surgery) measuring > 3cm in greatest dimension
Participants may not be receiving any other study agents
History of adverse reaction to radiotherapy
Participants receiving any medications or substances that are known to cause ototoxicity are ineligible
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Pregnant women
Individuals with a history of malignancy are ineligible except for the following circumstances. Individuals with a history of malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be a low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell squamous cell carcinoma of the skin
HIV-positive individuals on combination antiretroviral therapy
Patients with co-existing major ear disease, such as chronic otitis, Menieres disease, or otosclerosis
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note